Randomized, double‐blind, placebo‐controlled 8‐week trial of the efficacy, safety, and tolerability of 5, 10, and 20 mg/day vortioxetine in adults with major depressive disorder

By  

PSYCHIATRY AND CLINICAL NEUROSCIENCES, Vol. 72, Iss. 2, 2018-02 ,pp. : 64-72

John Wiley & Sons Inc

Access to resources Recommend Favorite

A randomized, double-blind trial of 2.5 mg and 5 mg vortioxetine (Lu AA21004) versus placebo for 8 weeks in adults with major depressive disorder

By Mahableshwarkar Atul R.   Jacobsen Paula L.   Chen Yinzhong  

Current Medical Research and Opinion, Vol. 29, Iss. 3, 2013-03 ,pp. : 217-226

Informa Healthcare

Access to resources Recommend Favorite

Open-Label Placebo for Major Depressive Disorder: A Pilot Randomized Controlled Trial

By  

Psychotherapy and Psychosomatics, Vol. 81, Iss. 5, 2012-08 ,pp. : 312-314

Karger

Access to resources Recommend Favorite

Maintenance of Clinical and Radiographic Benefit With Intravenous Golimumab Therapy in Patients With Active Rheumatoid Arthritis Despite Methotrexate Therapy: Week‐112 Efficacy and Safety Results of the Open‐Label Long‐Term Extension of a Phase III, Double‐Blind, Randomized, Placebo‐Controlled Trial

By  

ARTHRITIS CARE AND RESEARCH, Vol. 67, Iss. 12, 2015-12 ,pp. : 1627-1636

John Wiley & Sons Inc

Access to resources Recommend Favorite

Efficacy and safety of dapagliflozin monotherapy in people with Type 2 diabetes: a randomized double‐blind placebo‐controlled 102‐week trial

By  

DIABETIC MEDICINE, Vol. 32, Iss. 4, 2015-04 ,pp. : 531-541

John Wiley & Sons Inc

Access to resources Recommend Favorite